Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kirin Pharma, Kyowa Hakko Announce Restructuring of R&D Systems
April 14, 2008
- Mochida to Undertake Challenges in New Fields
April 14, 2008
- Industry Calls For Development of Toxicity Screening Tools Using iPS Cells
April 14, 2008
- Mediceo Paltac to Offer Prices to All Customers within April
April 14, 2008
- J-CLIPNET Ties Up with KoNECT of South Korea
April 14, 2008
- Korosho Asks Semi-Public Hospital Groups, Idaikyo, to Cooperate to Improve Business Practices
April 14, 2008
- R&D NEWS IN BRIEF
April 14, 2008
- BUSINESS NEWS IN BRIEF
April 14, 2008
- JACRI Approves Mid-Term Strategy to Expand Market for Reagents
April 14, 2008
- Mitsuo Sawai to Be Promoted to President of Sawai Pharm.
April 14, 2008
- LDP Calls For Acceleration of Medical Devices Review Process
April 14, 2008
- GEDA Inaugurated to Popularize Generic Substitution
April 14, 2008
- TOPICS／Eli Lilly Japan Adds Information on Counterfeit Cialis to Website
April 14, 2008
- All Prescriptions Issued by Some Hospitals Prohibit Use of Generics: NPhA Report
April 14, 2008
- Access to Drugs in Developing Countries Focused on at JPMA Forum
April 14, 2008
- Aiming at Eliminating "Drug Lag": New PMDA Chief Executive
April 7, 2008
- Long QT Risk Can Be Assessed Using Proarrhythmia Model
April 7, 2008
- Chuikyo Approves NHI Prices for 21 Products (14 APIs)
April 7, 2008
- Toyama Chemical to Review Licensing Policy
April 7, 2008
- TOPICS／Pfizer Starts Publicity Campaign on Growth Disorders in Girls
April 7, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…